Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05879107 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,113
- Enrollment target
NCT05879107 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,113 participants.
The verdict
NCT05879107, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,113 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
Interventions
- BIOLOGICAL PCV20
- BIOLOGICAL RSVPreF3 OA investigational vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,113 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05879107
The ClinicalTrials.gov registry entry for NCT05879107 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PCV20 is the first listed.
NCT05879107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05879107 about?
NCT05879107 is a clinical study titled "Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults". The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
What is the current status of trial NCT05879107?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,113 participants. The study started on 2023-05-26. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT05879107?
The interventions under investigation include: PCV20 (BIOLOGICAL), RSVPreF3 OA investigational vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05879107?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.